176 related articles for article (PubMed ID: 25837824)
1. Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines.
Hausmann S; Brandt E; Köchel C; Einsele H; Bargou RC; Seggewiss-Bernhardt R; Stühmer T
PLoS One; 2015; 10(4):e0122689. PubMed ID: 25837824
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
3. INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas.
Chi MN; Guo ST; Wilmott JS; Guo XY; Yan XG; Wang CY; Liu XY; Jin L; Tseng HY; Liu T; Croft A; Hondermarck H; Scolyer RA; Jiang CC; Zhang XD
Oncotarget; 2015 Nov; 6(37):39891-907. PubMed ID: 26573229
[TBL] [Abstract][Full Text] [Related]
4. Second AKT: the rise of SGK in cancer signalling.
Bruhn MA; Pearson RB; Hannan RD; Sheppard KE
Growth Factors; 2010 Dec; 28(6):394-408. PubMed ID: 20919962
[TBL] [Abstract][Full Text] [Related]
5. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
Rodgers SJ; Ferguson DT; Mitchell CA; Ooms LM
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28082369
[TBL] [Abstract][Full Text] [Related]
6. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
7. SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.
Gasser JA; Inuzuka H; Lau AW; Wei W; Beroukhim R; Toker A
Mol Cell; 2014 Nov; 56(4):595-607. PubMed ID: 25458846
[TBL] [Abstract][Full Text] [Related]
8. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
9. INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.
Jin H; Yang L; Wang L; Yang Z; Zhan Q; Tao Y; Zou Q; Tang Y; Xian J; Zhang S; Jing Y; Zhang L
J Exp Clin Cancer Res; 2018 Jan; 37(1):8. PubMed ID: 29343273
[TBL] [Abstract][Full Text] [Related]
10. Serum and glucocorticoid kinase 3 at 8q13.1 promotes cell proliferation and survival in hepatocellular carcinoma.
Liu M; Chen L; Chan TH; Wang J; Li Y; Li Y; Zeng TT; Yuan YF; Guan XY
Hepatology; 2012 Jun; 55(6):1754-65. PubMed ID: 22262416
[TBL] [Abstract][Full Text] [Related]
11. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.
Tu Y; Gardner A; Lichtenstein A
Cancer Res; 2000 Dec; 60(23):6763-70. PubMed ID: 11118064
[TBL] [Abstract][Full Text] [Related]
12. The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.
Bago R; Sommer E; Castel P; Crafter C; Bailey FP; Shpiro N; Baselga J; Cross D; Eyers PA; Alessi DR
EMBO J; 2016 Sep; 35(17):1902-22. PubMed ID: 27481935
[TBL] [Abstract][Full Text] [Related]
13. MiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K/SGK3/β-catenin signaling pathways.
Kong X; Liu F; Gao J
Oncotarget; 2016 Oct; 7(40):66051-66060. PubMed ID: 27602769
[TBL] [Abstract][Full Text] [Related]
14. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
Steinbrunn T; Stühmer T; Sayehli C; Chatterjee M; Einsele H; Bargou RC
Br J Haematol; 2012 Nov; 159(4):430-40. PubMed ID: 22985491
[TBL] [Abstract][Full Text] [Related]
15. Phosphoproteomics reveals that the hVPS34 regulated SGK3 kinase specifically phosphorylates endosomal proteins including Syntaxin-7, Syntaxin-12, RFIP4 and WDR44.
Malik N; Nirujogi RS; Peltier J; Macartney T; Wightman M; Prescott AR; Gourlay R; Trost M; Alessi DR; Karapetsas A
Biochem J; 2019 Oct; 476(20):3081-3107. PubMed ID: 31665227
[TBL] [Abstract][Full Text] [Related]
16. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of activation of SGK3 by growth factors via the Class 1 and Class 3 PI3Ks.
Malik N; Macartney T; Hornberger A; Anderson KE; Tovell H; Prescott AR; Alessi DR
Biochem J; 2018 Jan; 475(1):117-135. PubMed ID: 29150437
[TBL] [Abstract][Full Text] [Related]
18. Biallelic loss of FAM46C triggers tumor growth with concomitant activation of Akt signaling in multiple myeloma cells.
Kanasugi J; Hanamura I; Ota A; Karnan S; Lam VQ; Mizuno S; Wahiduzzaman M; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Takami A
Cancer Sci; 2020 May; 111(5):1663-1675. PubMed ID: 32176823
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro.
Zhang H; Chen J; Zeng Z; Que W; Zhou L
Int J Mol Med; 2013 May; 31(5):1127-34. PubMed ID: 23503641
[TBL] [Abstract][Full Text] [Related]
20. Cyclophilin A as a downstream effector of PI3K/Akt signalling pathway in multiple myeloma cells.
Lin ZL; Wu HJ; Chen JA; Lin KC; Hsu JH
Cell Biochem Funct; 2015 Dec; 33(8):566-74. PubMed ID: 26833980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
